News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue …
Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from "strong buy" to "buy" due to revenue falling short of expectations, despite beating EPS estimates. The broader analyst consensus remains "hold" with an average price target of $17.67. Insider buying, including a significant purchase by the …
Aurinia Pharmaceuticals (AUPH) announced its Q2 2026 earnings, reporting an EPS of $0.28, surpassing the consensus estimate of $0.24. However, quarterly revenue of $58.57 million fell short of analysts' expectations. The company also provided FY 2026 revenue guidance of $315.0 million-$325.0 million, slightly below …
Aurinia Pharmaceuticals Inc. reported its 2026 quarterly results, with revenue reaching $83.22M and diluted EPS of $0.28, marking significant increases compared to the previous year. The growth was attributed to higher product sales, improved operating performance, and increased market penetration of LUPKYNIS. The company …
Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 revenue guidance. This performance reinforces the company's near-term outlook for its LUPKYNIS drug, despite ongoing concerns about its reliance on a single product and future pipeline development. …
Aurinia Pharmaceuticals announced strong financial results for the three and six months ended June 30, 2026, with significant increases in total revenue, net product sales, and net income compared to the previous year. The company also reiterated its 2026 revenue guidance and provided updates …
Aurinia Pharmaceuticals Inc. (AUPH) reported Q2 revenue of $83.2 million, surpassing the FactSet estimate of $80.4 million. The article also briefly mentions Unity Software's Q4 earnings, which showed a 35% year-over-year revenue increase to $609 million, exceeding the consensus estimate, despite a quarterly loss …
Aurinia Pharmaceuticals announced its Q2 2026 financial results, reporting $83.2 million in revenue and $37.4 million in net income. The company also reiterated its full-year 2026 revenue guidance of $315 million to $325 million. Key highlights include strong sales for LUPKYNIS and advancements in …
Aurinia Pharmaceuticals (AUPH) reported strong double-digit year-over-year growth in revenue and net income, primarily due to LUPKYNIS sales and improved margins. The company's 2026 guidance anticipates continued growth in revenue and product sales. Additionally, new clinical programs and share repurchases indicate ongoing positive business …
Aurinia Pharmaceuticals (AUPH) is expanding its clinical pipeline with a new Phase 1/2 trial for aritinercept, targeting generalized myasthenia gravis. The double-blind, placebo-controlled study will investigate the safety and efficacy of the dual BAFF/APRIL inhibitor in improving muscle weakness in this chronic autoimmune condition. …
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is showing weak near and mid-term sentiment, challenging a positive long-term outlook, with support currently being tested. The article provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. It highlights a significant …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) generated $283.06 million USD in revenue last year, primarily from its Therapeutic Drugs segment. This marks an increase from the previous year's $235.13 million USD. The United States was the largest contributor to revenue, accounting for $263.84 million USD.
This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock currently trades between a resistance of $16.58 and support of $14.31, making it suitable for range-bound swing trading. …
This article provides a risk assessment for Aurinia Pharmaceuticals Inc (AUPH), detailing its current risk score, beta value, and various volatility and liquidity metrics. AUPH has a risk assessment score of 7.19, ranking 16 out of 384 in its industry, and a beta of …
Aurinia Pharmaceuticals Inc. is set to release its second-quarter results, with analysts expecting earnings of $0.23 per share on revenue of $80.6 million. Investors will focus on the continued revenue growth of its lupus treatment LUPKYNIS and the company's profit margins, especially since sequential …
Aurinia Pharmaceuticals Inc (AUPH) has a current valuation score of 5.10, placing it in the lower ranks of the Biotechnology & Medical Research industry. Its P/E ratio is 6.71, significantly below its recent high but above its recent low. Key valuation metrics like P/B, …
Aurinia Pharmaceuticals Inc. generated €241.00 million in revenue last year, primarily from its Therapeutic Drugs segment. This represents an increase from the previous year's revenue of €227.13 million. The United States was the largest contributor to this revenue, accounting for €224.64 million last year.
This article provides an in-depth cash flow statement analysis for Aurinia Pharmaceuticals Inc (AUPH), offering both quarterly and annual data. It details operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The page also includes …
Aurinia Pharmaceuticals Inc. (AUPH) shows healthy fundamentals and high growth potential, though its valuation is considered fair. Analysts have given the stock a "Buy" rating with a target price of $17.00, suggesting an 8.70% upside. The company specializes in therapies for autoimmune diseases, with …
Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to release its Q2'26 earnings on July 30th. The company anticipates revenue of $80.45 million and earnings per share (EPS) of $0.24 for the quarter. This article provides a historical overview of AUPH's reported and estimated revenues and …
Aurinia Pharmaceuticals Inc (AUPH) is showing weak near and mid-term sentiment, despite a strong long-term outlook. The stock is currently testing support, and if it holds, resistance is expected next, with an exceptional risk-reward setup targeting an 11.4% gain. The article outlines different AI-generated …
This article provides an overview of Aurinia Pharmaceuticals Inc.'s (AUPH) earnings data, including upcoming and historical EPS and revenue reports. It highlights past earning beats and lists recent news and trending discussions related to the company. The company's next earnings report for Q2 '26 …
This article provides fundamental and financial data for Aurinia Pharmaceuticals Inc (AUPH), including its current stock price, market capitalization, P/E ratio, and 52-week high/low. It also lists recent news regarding the company, such as its upgrade to "Strong Buy" by Zacks and the initiation …
Aurinia Pharmaceuticals reported strong Q1 2026 results, with total revenue increasing 24% year-over-year to $77.7 million, driven by higher LUPKYNIS sales. Net income surged 48% to $34.4 million, and operating cash flows significantly improved. The company also saw significant management changes and provided positive …
Aurinia Pharmaceuticals (AUPH) released a proxy filing summary detailing strong 2024 LUPKYNIS sales, cash flow, and share repurchases. Shareholders will vote on directors, auditor appointment, a non-binding say-on-pay, and an amendment to the Equity Incentive Plan. The company also highlighted its updated corporate governance, …
Search by ticker symbol or company name and select a result to open its chart.